Fractyl Health (NASDAQ:GUTS) Posts Quarterly Earnings Results

Fractyl Health (NASDAQ:GUTS) issued its earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.02, Zacks reports. The business had revenue of $0.01 million for the quarter.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS traded down $0.01 during trading on Wednesday, reaching $2.42. 294,155 shares of the company traded hands, compared to its average volume of 317,785. The company’s 50 day moving average is $2.65 and its two-hundred day moving average is $4.08. The firm has a market capitalization of $115.99 million and a PE ratio of -0.20. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40. Fractyl Health has a 52 week low of $1.74 and a 52 week high of $14.50.

Insider Activity

In related news, insider Jay David Caplan sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total transaction of $188,500.00. Following the completion of the transaction, the insider now directly owns 30,484 shares in the company, valued at $88,403.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.